DR. CONSTANCE TRANDAFIR DUTTON, N.D.
Dietitian and Nutritionist at Costa Verde Blvd, San Diego, CA
License number
California ND358
Category
Naturopathic
Type
Naturopath
Address
Address
2
8950 Costa Verde Blvd #4326, San Diego, CA 92122
530 Lomas Sant Fe Dr SUITE B-1, Solana Beach, CA 92075
530 Lomas Sant Fe Dr SUITE B-1, Solana Beach, CA 92075
Phone
(425) 802-5462
(858) 755-8959 (Fax)
(858) 755-8959 (Fax)
Personal information
See more information about CONSTANCE TRANDAFIR DUTTON at radaris.comName
Address
Phone
8950 Costa Verde Blvd APT 43, San Diego, CA 92122
985 Arroyo Dr, Chula Vista, CA 91910
Chula Vista, CA
985 Arroyo Dr, Chula Vista, CA 91910
Professional information
See more information about CONSTANCE TRANDAFIR DUTTON at trustoria.com
Constance T Dutton, San Diego CA - ND (Doctor of Naturopathic Medicine)
Constance T Dutton, San Diego CA - ND (Doctor of Naturopathic Medicine)
Specialties:
Naturopathy
Address:
8950 Costa Verde Blvd SUITE 4326, San Diego 92122
(858) 755-8959 (Fax)
(858) 755-8959 (Fax)
Languages:
English
Methods For Chronic Pain Management And Treatment Using Hcg
Methods For Chronic Pain Management And Treatment Using Hcg
US Patent:
2012026, Oct 18, 2012
Filed:
Dec 5, 2011
Appl. No.:
13/311250
Inventors:
Constance T. Dutton - San Diego CA, US
Assignee:
NEURALIGHT HD, LLC - Incline Village NV
International Classification:
A61M 5/31, A61M 5/178, A61P 25/00, A61K 38/24, A61K 9/12
US Classification:
604 92, 514 98, 424 45, 604207, 604187
Abstract:
A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug.
Methods For Chronic Pain Management And Treatment Using Hcg
Methods For Chronic Pain Management And Treatment Using Hcg
US Patent:
2012026, Oct 18, 2012
Filed:
Aug 16, 2011
Appl. No.:
13/211101
Inventors:
Constance T. Dutton - San Diego CA, US
International Classification:
G06Q 90/00, A61P 29/00, A61K 38/24
US Classification:
705500, 514 97
Abstract:
A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (HCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, and a label that identifies chronic pain or central sensitization as an indication of the drug.
Methods For Chronic Pain Management And Treatment Using Hcg
Methods For Chronic Pain Management And Treatment Using Hcg
US Patent:
2013019, Aug 1, 2013
Filed:
Oct 2, 2012
Appl. No.:
13/633739
Inventors:
Constance T. Dutton - San Diego CA, US
Assignee:
NEURALIGHT HD, LLC - Incline Village NV
International Classification:
A61K 38/24, A61M 5/315
US Classification:
514 98, 604506
Abstract:
A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug.